Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France.

Date publication

avril 2025

Journal

PharmacoEconomics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NERICH Virginie

Tous les auteurs :
Pilz MJ, Seyringer S, Nerich V, King MT, Norman R, Gamper EM,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40287928

Résumé

The Quality of Life Utility - Core 10 Dimensions (QLU-C10D) is a disease-specific preference-based measure (PBM) designed to obtain health state utility values from patients with cancer. Previously, satisfactory psychometric properties were established from retrospective trial analyses using clinical anchors. This study aimed to validate the QLU-C10D against two generic PBMs in a prospective sample of Austrian and French patients with cancer using patient-reported anchors.

Référence

Pharmacoeconomics. 2025 04 27;: